Final result of a phase I study of combination of pasireotide (SOM 230) LAR plus gemcitabine in metastatic pancreatic cancer (MPC).
Yaman Suleiman
No relevant relationships to disclose
Gregory M. Springett
No relevant relationships to disclose
Erin M. Siegel
No relevant relationships to disclose
David Shibata
No relevant relationships to disclose
William J. Fulp
No relevant relationships to disclose
Richard D. Kim
No relevant relationships to disclose